Decision Resources projects same U.S., Europe patient share of ulcerative colitis biologic
WALTHAM, Mass. A new report by Decision Resources revealed that a biological therapy with a mechanism of action other than tumor necrosis factor-alpha inhibitors, used for the treatment of moderate to severe ulcerative colitis, would earn a 25% patient share in both the United States and Europe.
The report, "Ulcerative Colitis: Gastroenterologists Identify Emerging Drugs That Will Challenge the Benchmark Therapy Infliximab for Moderate to Severe UC," finds that two emerging TNF-alpha inhibitors -- Abbott/Eisai's Humira and Centocor Ortho Biotech/Merck/Mitsubishi Tanabe Pharma/Janssen's Simponi -- will earn Decision Resources' proprietary clinical gold standard status for ulcerative colitis in 2013 following their approval for the indication. Both Humira and Simponi have competitive advantages over sales-leader Remicade in efficacy, delivery, and safety and tolerability.
"Although clinical trial data are limited, interviewed experts believe that both Humira and Simponi's fully human composition will translate into incremental advantages in efficacy for maintenance of remission and maintenance of response compared to Remicade, which is a chimeric monoclonal antibody," said Decision Resources analyst Kathryn Benton.